CymaBay Therapeutics Company Profile (NASDAQ:CBAY)

About CymaBay Therapeutics (CBAY)

CymaBay Therapeutics logoCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CBAY
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $3.91
  • 50 Day Moving Average: $3.16
  • 200 Day Moving Average: $2.19
  • 52-Week Range: $1.02 - $4.44
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.93
  • P/E Growth: 0.00
  • Market Cap: $86.52M
  • Outstanding Shares: 23,447,000
  • Beta: 1.17
Profitability:
  • Return on Equity: -136.00%
  • Return on Assets: -76.09%
Debt:
  • Debt-to-Equity Ratio: 0.67%
  • Current Ratio: 3.16%
  • Quick Ratio: 3.16%

Analyst Ratings

Consensus Ratings for CymaBay Therapeutics (NASDAQ:CBAY) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (62.60% upside)

Analysts' Ratings History for CymaBay Therapeutics (NASDAQ:CBAY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/30/2017HC WainwrightUpgradeNeutral -> Buy$2.50 -> $6.00N/AView Rating Details
7/1/2016Roth CapitalInitiated CoverageBuyN/AView Rating Details
7/21/2015Piper Jaffray CompaniesInitiated CoverageOverweight$4.00N/AView Rating Details
5/8/2015Stifel NicolausReiterated RatingBuy$15.00 -> $9.00N/AView Rating Details
(Data available from 3/23/2015 forward)

Earnings

Earnings History for CymaBay Therapeutics (NASDAQ:CBAY)
Earnings by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Earnings History by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2017        
3/23/2017Q4 2016($0.28)N/AView Earnings Details
5/12/2016Q1($0.28)($0.29)ViewListenView Earnings Details
3/29/2016Q4($0.35)($0.26)ViewListenView Earnings Details
11/12/2015Q315($0.33)($0.27)ViewListenView Earnings Details
8/10/2015Q215($0.42)($0.09)ViewListenView Earnings Details
5/7/2015($0.43)($0.44)ViewN/AView Earnings Details
3/18/2015Q414($0.47)($0.87)ViewN/AView Earnings Details
11/12/2014Q314($0.47)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CymaBay Therapeutics (NASDAQ:CBAY)
Current Year EPS Consensus Estimate: $-1.13 EPS
Next Year EPS Consensus Estimate: $-0.94 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.30)($0.30)($0.30)
Q3 20161($0.31)($0.31)($0.31)
Q4 20161($0.26)($0.26)($0.26)
Q1 20171($0.28)($0.28)($0.28)
Q2 20171($0.29)($0.29)($0.29)
Q3 20171($0.20)($0.20)($0.20)
Q4 20171($0.21)($0.21)($0.21)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CymaBay Therapeutics (NASDAQ:CBAY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CymaBay Therapeutics (NASDAQ:CBAY)
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 27.88%
Insider Trades by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Insider Trades by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/6/2016Robert James WillsDirectorBuy25,000$2.43$60,750.00View SEC Filing  
4/15/2016Charles McwherterVPBuy3,000$1.68$5,040.00View SEC Filing  
4/5/2016Sujal ShahCFOBuy55,000$1.39$76,450.00View SEC Filing  
4/4/2016Sujal ShahCFOBuy22,000$1.39$30,580.00View SEC Filing  
9/11/2015Carl GoldfischerDirectorSell46,729$2.74$128,037.46View SEC Filing  
8/14/2015Emster Kurt VonDirectorBuy90,000$2.69$242,100.00View SEC Filing  
7/20/2015Emster Kurt VonDirectorBuy1,600,000$2.81$4,496,000.00View SEC Filing  
5/18/2015Sujal ShahCFOBuy10,000$3.40$34,000.00View SEC Filing  
5/18/2015Wart Harold VanCEOBuy7,500$3.34$25,050.00View SEC Filing  
5/15/2015Charles McwherterVPBuy2,000$3.16$6,320.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CymaBay Therapeutics (NASDAQ:CBAY)
Latest Headlines for CymaBay Therapeutics (NASDAQ:CBAY)
Source:
DateHeadline
News IconCymaBay Therapeutics Inc (CBAY) Scheduled to Post Quarterly Earnings on Thursday (NASDAQ:CBAY)
www.americanbankingnews.com - March 22 at 7:34 AM
prnewswire.com logoResearch Reports Coverage on Biotech Stocks -- VIVUS, Ultragenyx ... - PR Newswire (press release) (NASDAQ:CBAY)
www.prnewswire.com - March 18 at 5:25 AM
finance.yahoo.com logoWill Cymabay Therapeutics (CBAY) Continue to Surge Higher? (NASDAQ:CBAY)
finance.yahoo.com - March 15 at 4:29 PM
finance.yahoo.com logoCymaBay Therapeutics to Present at Two Investor Conferences in March (NASDAQ:CBAY)
finance.yahoo.com - March 9 at 4:45 PM
zacks.com logoProgenics Pharmaceuticals (PGNX) in Focus: Stock Gains 8.3% (NASDAQ:CBAY)
www.zacks.com - February 28 at 9:16 AM
finance.yahoo.com logoCan The Uptrend Continue for Cymabay Therapeutics (CBAY)? (NASDAQ:CBAY)
finance.yahoo.com - February 14 at 4:52 PM
finance.yahoo.com logoCerner's EHR Platform to Enhance Health Care at San Juan NGO (NASDAQ:CBAY)
finance.yahoo.com - February 13 at 4:46 PM
finance.yahoo.com logo5 Breakout Stocks for Superior Returns (NASDAQ:CBAY)
finance.yahoo.com - February 10 at 3:47 PM
finance.yahoo.com logoCymabay Therapeutics (CBAY) Rises: Stock Moves 9.2% Higher (NASDAQ:CBAY)
finance.yahoo.com - February 9 at 4:28 PM
streetinsider.com logoCymaBay Therapeutics (CBAY) Prices 5.2M Offering of Common Stock at $1.93/Share - StreetInsider.com (NASDAQ:CBAY)
www.streetinsider.com - February 3 at 4:24 PM
streetinsider.com logoCymaBay Therapeutics (CBAY) Prices 5.2M Offering of Common Stock at $1.93/Share (NASDAQ:CBAY)
www.streetinsider.com - February 2 at 4:25 PM
us.rd.yahoo.com logoCymaBay Announces Pricing of Public Offering of Common Stock (NASDAQ:CBAY)
us.rd.yahoo.com - February 2 at 4:25 PM
streetinsider.com logoCymaBay Therapeutics (CBAY) Plans Public Offering of Common Stock (NASDAQ:CBAY)
www.streetinsider.com - February 2 at 2:25 AM
streetinsider.com logoAfter-Hours Stock Movers 02/01: (MJN) (ESIO) (FB) Higher; (AVIR) (SFLY) (MLNX) Lower (more...) (NASDAQ:CBAY)
www.streetinsider.com - February 1 at 9:25 PM
us.rd.yahoo.com logo4:02 pm CymaBay Therapeutics announces that it intends to offer and sell shares of its common stock; size not disclosed (NASDAQ:CBAY)
us.rd.yahoo.com - February 1 at 9:25 PM
finance.yahoo.com logoCymaBay Announces Proposed Public Offering of Common Stock (NASDAQ:CBAY)
finance.yahoo.com - February 1 at 4:24 PM
finance.yahoo.com logoCymaBay Therapeutics upgraded by H.C. Wainwright (NASDAQ:CBAY)
finance.yahoo.com - January 30 at 4:11 PM

Social

Frequently Asked Questions for CymaBay Therapeutics (NASDAQ:CBAY)

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics Inc (NASDAQ:CBAY) posted its earnings results on Thursday, May, 12th. The company reported ($0.29) EPS for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.01.

When will CymaBay Therapeutics make its next earnings announcement?

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.

Where is CymaBay Therapeutics' stock going? Where will CymaBay Therapeutics' stock price be in 2017?

2 analysts have issued 12 month target prices for CymaBay Therapeutics' shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate CymaBay Therapeutics' share price to reach $6.00 in the next twelve months.

Who owns CymaBay Therapeutics stock?

CymaBay Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Kingdon Capital Management L.L.C. (4.01%), J. Goldman & Co LP (1.41%) and Renaissance Technologies LLC (0.50%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Emster Kurt Von, Robert James Wills, Sujal Shah and Wart Harold Van.

Who sold CymaBay Therapeutics stock? Who is selling CymaBay Therapeutics stock?

CymaBay Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C. and Renaissance Technologies LLC.

Who bought CymaBay Therapeutics stock? Who is buying CymaBay Therapeutics stock?

CymaBay Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including J. Goldman & Co LP. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Emster Kurt Von, Robert James Wills, Sujal Shah and Wart Harold Van.

How do I buy CymaBay Therapeutics stock?

Shares of CymaBay Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of CymaBay Therapeutics stock cost?

One share of CymaBay Therapeutics stock can currently be purchased for approximately $3.69.

CymaBay Therapeutics (CBAY) Chart for Thursday, March, 23, 2017

This page was last updated on 3/23/2017 by MarketBeat.com Staff